Benchmark International 
Archives
Political and economic uncertainty caused pharma M&A to slacken off in 2016, seeing deal values in the sector falling to $273.7bn from $392.4bn the previous year. While 2016 was far from catastrophic for pharma M&A it failed to reach the all-time highs achieved from the mega-deals in 2015, and the collapse of the $160bn mega-deal between Pfizer and Allergan was just one of the year’s setbacks for the sector. Despite this, M&A… Read More
Following a summer of uncertainty post Brexit, investors all over the world are returning from summers spent on the beach, ready to do some serious M&A business to close out the year. We have seen a comparatively quiet year for M&A when you look at the figures for 2015, with deal values in the UK around half of the $215 billion that were announced at the same time in 2015 (Thomson Reuters… Read More
Think healthcare M&A is on its way out in 2016? Think again. Following the surprising failure in April of the deal between Pfizer and Allergan, many analysts have raised concerns that a similar pattern will ensue within healthcare deal making. While the collapse of the $160bn deal was unexpected, and brought total value of abandoned deals this year to its highest since the eve of the financial crisis at $376bn, industry experts… Read More
The corporate industry world has borne witness to some of the mega deals being signed throughout the year. Pharmaceutical giant Pfizer announced as $160 billion merger with Allergan. A deal that was, according to Bloomberg, “the largest ever deal in the history of healthcare industry and second biggest deal overall on record”. The chemical industry has also been going through the consolidation process, with leading chemical companies, DuPont and Dow, agreeing to… Read More